🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Post Graduate Institute of Medical Education and Research, Chandigarh clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our India register with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor. Synced 26 Sep 2026
29Current trials
21Recruiting now
15Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 29 current clinical trials in our India register. 21 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Prednisolone, Itraconazole and Carvedilol. The most-studied condition is Cirrhotic Cardiomyopathy.

ClinicalTrials.gov trials by status

  • Recruiting2172%
  • Not yet open517%
  • Active, closed310%

Trials by phase

  • Not applicable828%
  • Phase 3621%
  • Phase 4621%
  • Observational517%
  • Phase 2/327%
  • Phase EARLY_PHASE113%
  • Phase 113%
01

Clinical trials sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh

29 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
NCT07322237 · Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors
Phase 4 Recruiting 2026-04 India
Cardiac Dysfunction in Patients with Fatty Liver Disease
NCT06386094 · NAFLD, Cardiac Disease, Fatty Liver
Observational Recruiting 2023-07 India
Contact Cast Versus Posterior Slab as Offloading Modality for Charcot Neuroarthropathy
NCT06573554 · Charcot Neuroarthropathy
Not applicable Recruiting 2024-12 India
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
NCT06962202 · Cushing Syndrome
Observational Recruiting 2022-08 India
Home-based Pulmonary Rehabilitation in Interstitial Lung Disease
NCT07830602 · Interstitial Lung Diseases
Not applicable Recruiting 2025-11 India
A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
NCT06447402 · Chronic Pulmonary Aspergillosis, CPA, Aspergilloma
Phase 3 Recruiting 2024-06 India
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population
NCT05691036 · ClinicalTrials.gov ↗ · Intrahepatic Cholestasis of Pregnancy, Genetic Mutation, Health Related Quality of Life
Observational Recruiting 2022-12 India
RCT of Nintedanib in Fibrotic Sarcoidosis
NCT06479603 · ClinicalTrials.gov ↗ · Sarcoidosis, Pulmonary
Phase 4 Recruiting 2024-06 India
Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess
NCT06847126 · ClinicalTrials.gov ↗ · Liver Abscess
Phase 3 Recruiting 2025-02 India
Microplastics, Cirrhosis and Portal Hypertension
NCT07280390 · ClinicalTrials.gov ↗ · Cirrhosis, Microplastics, Portal Hypertension Related to Cirrhosis
Observational Recruiting 2026-05 India
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
NCT06431919 · ClinicalTrials.gov ↗ · Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver
Not applicable Recruiting 2025-06 India
Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology
NCT06095466 · ClinicalTrials.gov ↗ · Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Cardiac Disease
Observational Recruiting 2023-07 India
Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy
NCT07184801 · ClinicalTrials.gov ↗ · Medical Thoracoscopy
Phase 3 Recruiting 2025-10 India
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).
NCT04472845 · ClinicalTrials.gov ↗ · Breast Cancer, Hypofractionation, Radiotherapy Side Effect
Not applicable Recruiting 2021-03 India
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
NCT06538077 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
Phase 4 Recruiting 2025-02 India
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
NCT06174922 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis
Phase 3 Recruiting 2023-12 India
Efficacy of Pregabalin for Diabetic Pruritus - A Randomized Controlled Study.
NCT06790537 · ClinicalTrials.gov ↗ · Diabetic Pruritus, Efficacy of Pregabalin in Controlling Diabetic Pruritus Severity
Phase 4 Recruiting 2025-04 India
Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis
NCT07395778 · ClinicalTrials.gov ↗ · Walled Off Pancreatic Necrosis, Acute Pancreatitis (AP), Endoscopic Ultrasound-Guided Drainage
Not applicable Recruiting 2025-10 India
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
NCT05444946 · ClinicalTrials.gov ↗ · Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Not applicable Recruiting 2022-06 India
Comparison of FDG-PET/CT and CECT-CAP as Upfront Imaging Modality for the Diagnosis of Pyrexia of Unknown Origin
NCT07816783 · ClinicalTrials.gov ↗ · Pyrexia
Not applicable Recruiting 2026-04 India
Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis
NCT07286643 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Cirrhotic Cardiomyopathy, Septic Shock
Not applicable Recruiting 2026-01 India
Efficacy of Diloxanide Furoate as Additional Luminal Agent Along With Metronidazole for the Treatment of Amoebic Liver Abscess
NCT07807150 · Liver Abscess, Amoebic Liver Abscess
Phase 3 Not yet open 2026-09 India
Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock
NCT06306001 · Neonatal Sepsis, Shock, Septic
Phase 2/3 Not yet open 2024-03 India
A Study of Itraconazole and Posaconazole for Chronic Pulmonary Aspergillosis
NCT07825259 · ClinicalTrials.gov ↗ · Chronic Pulmonary Aspergillosis
Phase 3 Not yet open 2026-11 India
Affordable Made-in-India Microspheres for Liver Cancer Therapy
NCT07436988 · ClinicalTrials.gov ↗ · Hepatecellular Carcinoma
Phase 1 Not yet open 2026-02 India
Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
NCT06654934 · ClinicalTrials.gov ↗ · Sarcoidosis
Phase 4 Not yet open 2024-11 India
Deflazacort Vs. Prednisolone in Acute-stage ABPA
NCT04227483 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis
Phase 2/3 Active, closed 2020-01 India
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
NCT06373523 · ClinicalTrials.gov ↗ · Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
Phase EARLY_PHASE1 Active, closed 2024-01 India
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
NCT05626387 · ClinicalTrials.gov ↗ · Hypersensitivity Pneumonitis
Phase 4 Active, closed 2022-11 India

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Post Graduate Institute of Medical Education and Research, Chandigarh trials

15 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Post Graduate Institute of Medical Education and Research, Chandigarh trials

47 conditions
Cirrhotic Cardiomyopathy4Chronic Pulmonary Aspergillosis3Allergic Bronchopulmonary Aspergillosis3Cirrhosis, Liver3Liver Abscess2Cirrhosis2Cardiac Disease2Decompensated Cirrhosis2Amoebic Liver Abscess1Empagliflozin1Cardiometabolic Risk Factors1NAFLD1Fatty Liver1MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease1Charcot Neuroarthropathy1Cushing Syndrome1Neonatal Sepsis1Shock, Septic1Interstitial Lung Diseases1CPA1Aspergilloma1Hepatic Steato-Fibrosis1Non-Alcoholic Fatty Liver Disease1Intrahepatic Cholestasis of Pregnancy1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in India2921

A trial with sites in more than one country appears in each of those registers.

05

Questions about Post Graduate Institute of Medical Education and Research, Chandigarh trials

How many clinical trials does Post Graduate Institute of Medical Education and Research, Chandigarh sponsor?

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 29 current trials on ClinicalTrials.gov in our India register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Post Graduate Institute of Medical Education and Research, Chandigarh trials recruiting?

Yes. 21 of its 29 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Post Graduate Institute of Medical Education and Research, Chandigarh testing?

Its current trials name 15 drugs and biologicals as interventions. The most frequent are Prednisolone (4), Itraconazole (3), Carvedilol (2), Dapagliflozin Tab (1) and Dexmedetomidine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.